Thoracic Neoplasms
Conditions
Keywords
Active Treatment
Brief summary
The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.
Detailed description
The investigators have developed an innovative mHealth platform that provides personalized recommendations based on Patient Reported Outcomes (PROs) records and the study of patient´s nutrigenomics and gut microbiome. The usability of the ALIBIRD mHealth platform prototype is being tested in a 28-week pilot study carried out at Infanta Sofía Hospital. A small group of stage IV thoracic neoplasms patients (n=20) were asked to participate. All the participants gave informed consent.
Interventions
DEVICEALIBIRD mHealth platform
Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health.
Sponsors
Hospital Infanta Sofia
Universidad Politecnica de Madrid
IMDEA Food
Instituto de Investigación en Ciencias de la Alimentación (CIAL)
Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with thoracic neoplasms, histologically or cytologically confirmed. * \< 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Patients receiving cancer treatment: chemotherapy, chemotherapy-immunotherapy, immunotherapy or biological therapy. * Patients with internet access and intermediate level in the use of technology (Smartphone, mobile applications, wearable) * Signed informed consent.
Exclusion criteria
* Patients with symptomatic brain metastases. * Patients with neurological impairment, dementia or psychiatric disorders. * Patients unable to follow the protocol due to psychological, social or geographic reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Usability and feasibility assesment | week 1 to 28 | Changes in Satisfaction System Usability Scale (SUS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Quality of life ( European Quality of Life-5 Dimensions 5 Levels questionnaire,EQ-5D-5L) from baseline | Week 1 to 28 | Quality of life assesment. The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. In the VAS the individual scores his or her health between two extremes, 0 and 100, the worst and best state of health imaginable. |
| Changes in physical activity (International Physical Activity Questionnaire,PAQ) | Week 1 to 28 | Physical activity assesment |
| Changes in sleep (Pittsburg questionnaire) | Week 1 to 28 | Sleep assesment |
| Changes in Quality of life ( The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13, EORTC QLQ-LC-13) | Week 1 to 28 | Quality of life assesment. The LC13 covers 13 typical symptoms of lung cancer patients, such as coughing, pain, dyspnea, sore mouth, peripheral neuropathy, and hair loss. questions along 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning) and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) All items are scored from 1 to 4 in relation to the presence of the symptom: not at all, a little, quite a bit, very much. |
| Changes in Mediterranean Diet Serving Score (MDSS) | Week 1 to 28 | Mediterranean adherence assesment |
| Changes is Hospital Anxiety and Depression Questionnaire (HADs) from baseline | Week 1 to 28 | Emotional status assesment. This is a scale containing two subscales with 7 anxiety symptoms (HADS-A) and 7 depression symptoms (HADS-D). The items are scored on a 4-point Likert frequency scale (0-3) with a total score ranging from 0 to 21 for each subscale, where a higher score is indicative of greater symptom severity. |
| Changes in Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) from baseline | Week 1 to 28 | Sexuality assesment |
| Changes is medication adherence (MMAS-8 questionnaire) | Week 1 to 28 | Medication adherence assesment |
| Changes in belief in medication (Beliefs about Medicines Questionnaire,BMQ) | Week 1 to 28 | Belief in medication assesment |
| Changes in toxicity (Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events, PRO-CTAE questionnaire) | week 1 to 28 | Toxicity assesment |
Countries
Spain
Outcome results
None listed